FDA approves Aerie glaucoma therapy Rocklatan

Aerie said late Tuesday FDA approved Rocklatan netarsudil/latanoprost to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The product is a fixed-dose combination of Aerie's Rhopressa netarsudil 0.02%, a dual inhibitor of Rho kinase and the norepinephrine transporter, and latanoprost 0.005%, a prostaglandin analog.

The approval comes two days before its March 14 PDUFA date. Aerie Pharmaceuticals Inc. (NASDAQ:AERI) plans to launch Rocklatan in May and said it will be sold at a "modest premium" to Rhopressa, but declined to disclose the price...